Gastric Cancer
Conditions
Brief summary
This is a phase I, multi-center clinical trial to evaluate the safety, tolerability, antitumor activities and pharmacokinetics of IN10018 as monotherapy or in combination with docetaxel in previously-treated locally advanced or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma.
Detailed description
Eligibility patients will be enrolled into the study and assigned to treatment groups: 1) IN10018 monotherapy group, and 2) IN10018+Docetaxel combination group. This study contains 2 parts of dose escalation and dose expansion for each treatment group. The monotherapy group will enroll patients failed to respond to standard therapy or standard or curative therapy does not exist or is not tolerable, and explore IN10018 monotherapy RP2D with the starting dose of IN10018 100mg QD per 3+3 design. The combination group will enroll patients who have disease progression within 3 months after at least first-line therapy, and explore IN10018+docetaxel RP2D with the starting dose of IN10018 100mg QD + docetaxel 75mg/m2 per 3+3 design. The dose expansion part will start after attaining the RP2D of IN10018 monotherapy and IN10018+docetaxel combination therapy.
Interventions
DRUGIN10018
IN10018 orally once daily at approximately the same time each day, to ensure a dose interval of approximately 24 hours.
DRUGDocetaxel
Docetaxel 75mg/m2 every 21 days a cycle.
Sponsors
InxMed (Shanghai) Co., Ltd.
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
* 1.Has histologically or cytologically confirmed diagnosis of locally advanced and/or metastatic gastric or GEJ adenocarcinoma. * For monotherapy, participants need to be failed to respond to standard therapy or standard or curative therapy does not exist or is not tolerable. * For combination therapy, participants need to have disease progression within 3 months after at least first-line therapy. * 2.Has at least one measurable tumor lesion per RECIST 1.1. * 3.Has an ECOG performance status of 0 or 1. * 4.Estimated life expectancy is more than 3 months. * 5.Adequate organ and bone marrow functions. * 6.Has been fully informed and provided written informed consent for the study
Exclusion criteria
* 1.Has other histological types other than adenocarcinoma. * 2.For participants with HER2/neu positive tumors or have an unknown tumor status, need to match the following: * If HER2/neu positive, participant must have documentation of disease progression on trastuzumab or other anti-HER2/neu therapy. * Participants with unknown status must have their HER2/neu status determined locally. If HER2/neu-negative, the participant will be eligible. If HER2/neu-positive, the participant must have documentation of disease progression on trastuzumab or other anti-HER2/neu therapy. * 3.Has had disease progression after docetaxel/paclitaxel containing treatment (combination therapy only). * 4.Has received prior systemic therapies (i.e. chemotherapy, biotherapy, endocrinotherapy, and immunotherapy) within 4 weeks prior to start of study treatment. * 5.Has received prior radiotherapy within 2 weeks prior to start of study treatment. * 6.Has severe allergy or hypersensitivity to IN10018 and/or docetaxel, or any components used in their preparation or has contraindication for taxane therapy. For participants in monotherapy group, only restriction to IN10018 applies. * 7.Has severe renal disease or impaired renal function. * 8.Has an active infection requiring systemic therapy within 2 weeks prior to start of study treatment. * 9.Has a history or current evidence of interstitial lung disease.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Safety and tolerability in combination group | up to 24 months | Number of patients with adverse event in combination group; Number of patients with laboratory abnormalities, abnormal vital signs and abnormal 12-lead ECG in combination group |
| DLTs in combination group | 21 days | Number of patients with dose-limited toxicities (DLTs) in combination group |
| Phase II dose of IN10018 in combination with Docetaxel | up to 24 months | Determine the recommended phase II dose (RP2D) of IN10018 in combination with Docetaxel |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Duration of objective response (DOR) per RECIST v1.1. | up to 24 months | Defined as the time from start of the first documentation of CR or PR to the first documentation of disease progression or to death due to any cause, whichever comes first |
| Disease Control Rate (DCR) per RECIST v1.1. | up to 24 months | Defined as the proportion of patients with CR, PR, or stable disease (SD) |
| Progression-free survival (PFS) per RECIST v1.1. | up to 24 months | Defined as the time from start of study treatment to first documentation of disease progression or to death due to any cause, whichever comes first. |
| Overall survival (OS). | up to 30 months | Defined as the time from the start of any study treatment to the date of death due to any cause. |
| Pharmacokinetics (PK):AUC | up to 24 months | Area under the concentration-time curve (AUC). |
| Safety and tolerability in IN10018 monotherapy group | up to 24 months | Number of patients with adverse event in monotherapy group; Number of patients with laboratory abnormalities, abnormal vital signs and abnormal 12-lead ECG in monotherapy group |
| PK:Tmax | up to 24 months | Time to Cmax (Tmax). |
| PK:Ctrough | up to 24 months | Trough concentration (Ctrough). |
| PK:t1/2 | up to 24 months | Elimination half-life (t1/2). |
| PK:CL/F | up to 24 months | apparent clearance (CL/F). |
| PK:Vd/F | up to 24 months | Apparent volume of distribution (Vd/F). |
| Pharmacokinetics (PK):Cmax | up to 24 months | PK: Maximum concentration (Cmax). |
| DLTs in IN10018 monotherapy group | up to 24 months | Number of patients with dose-limited toxicities (DLTs) in monotherapy group |
| Objective response rate (ORR) per RECIST v1.1 | up to 24 months | Defined as the proportion of patients with complete response (CR) or partial response (PR). |
Countries
China
Outcome results
None listed